Is Fermenta Biotec. overvalued or undervalued?
As of July 1, 2025, Fermenta Biotec is considered an attractive investment with a PE ratio of 12.65, an EV to EBITDA of 9.25, and a PEG ratio of 0.02, indicating it is undervalued compared to peers like Sun Pharma and Cipla, and has significantly outperformed the Sensex with a one-year return of 99.19%.
As of 1 July 2025, the valuation grade for Fermenta Biotec has moved from very attractive to attractive, indicating a shift in perception regarding its investment potential. The company is currently assessed as undervalued. Key ratios include a PE ratio of 12.65, an EV to EBITDA of 9.25, and a PEG ratio of 0.02, which suggests that the stock is trading at a significant discount relative to its growth prospects.In comparison to its peers, Fermenta Biotec's valuation appears favorable; for instance, Sun Pharma has a PE ratio of 34.98, while Cipla stands at 23.21. This highlights Fermenta's relative attractiveness in the pharmaceuticals and biotechnology sector. Additionally, the company's recent stock performance has outpaced the Sensex, with a one-year return of 99.19% compared to the Sensex's 5.31%, further reinforcing its undervalued status in the market.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
